Recent Posts by ruxandralenz

SphingoTec to Present at the LifeSci Partners’ Summer Symposium

Hennigsdorf/Berlin, Germany – July 31, 2020 – Diagnostics company SphingoTec GmbH (“SphingoTec”) today announced that Dr Andreas Bergman, CEO, and Ferdinand von Humboldt, CFO, will be presenting a corporate overview at the Private Healthcare Company Virtual Summer Symposium, hosted by LifeSci Partners on August 4 and 5, 2020. SphingoTec develops and markets in-vitro diagnostic tests…
Read more

sphingotec launches point-of-care test for bio-ADM, a biomarker for life threatening endothelial dysfunction

Endothelial dysfunction is driving pathophysiological processes such as congestion in heart failure, shock in sepsis, and lung dysfunction in COVID-19 Bioactive Adrenomedullin (bio-ADM®) is a proprietary biomarker for real-time assessment of endothelial function in acute and critical care settings. High blood levels of bio-ADM® have been shown to predict septic shock, to diagnose residual congestion…
Read more

Sphingotec’s critical care biomarkers early diagnose risk of loss of endothelial, kidney and heart function in severely ill COVID-19 patients

Results of a consensus meeting of clinical experts investigating sphingotec’s diagnostic solutions for acute and critical care in COVID-19. sphingotec’s biomarkers penKid, bio-ADM, and DPP3 previously shown to predict the need for organ support in numerous critical care conditions also have utility in risk stratification of severely ill COVID-19 patients. Hennigsdorf/Berlin, Germany, June 18, 2020…
Read more

The cardiac depressant factor DPP3 is predicting organ failure in burn patients

DPP3 is a highly dynamic marker for predicting and monitoring cardiac depression in burn patients High DPP3 blood concentrations are indicating multiple organ failure and poor outcomes sphingotec commercializes a rapid CE-IVD test for DPP3 on its proprietary point-of-care platform Nexus IB10   Hennigsdorf/Berlin, Germany, May 14, 2020 – Diagnostics company SphingoTec GmbH (“sphingotec”) and…
Read more

Recent Comments by ruxandralenz

No comments by ruxandralenz yet.